Article
Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia.
Laboratory medicine - 2 Nov 2021
Mohammadi Fatemeh, Rostami Golale, Assad Dlnya, Shafiei Mohammad, Hamid Mohammad, Jalaeikhoo Hasan
Abstract excerpt
OBJECTIVE: To determine whether polymorphisms of SLC22A1 and SLCO1B3 genes could predict imatinib (IM) response and chronic myeloid leukemia (CML) risk. METHODS: We genotyped SLC22A1 (c.480G > C, c.1222A > G) and SLCO1B3 (c.334T > G, c.699G > A) polymorphisms in 132 patients with CML and 109 sex- and age-matched healthy subjects. The patients were evaluated for cytogenetic response by standard chromosome banding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.